Bioresorbable Sirolimus-eluting scaffold in de Novo Coronary Artery Lesions

Inclusion Criteria: Clinical inclusion criteria 1. Patients with an indication for PCI due to acute or chronic coronary syndrome 2. Patients who understand the study's objectives, voluntarily participate, sign the informed consent form, and are willing to undergo regular follow-up Angiographic inclusion criteria 1. De novo lesion(s) 2. Target vessel diameter of ≥ 2.5 mm to ≤ 4.00 mm, target lesion length ≤ 25 mm (visual estimation) 3. Target lesion is NOT 1. Severely calcified 2. In-stent restenosis 3. Diffused lesion requiring stent overlapping or more than one stent 4. Located in the left main, aorto-ostial, proximal LAD/LCX/RCA involving vessel ostia (stent coverage required within 3 mm of vessel ostia), surgical graft, myocardial bridge, or chronic total occlusion 5. Bifurcation requiring two stents or involving a side branch that is ≥ 2.5 mm in diameter 6. Located in the target vessel with severe tortuosity Exclusion Criteria: 1. Age \< 18 years, or \> 75 years 2. Patient is a woman who is pregnant or nursing 3. Patients who have received any stent implantation in the target vessel within one year 4. Patients required long-term oral anticoagulation 5. Known non-adherence to antiplatelet therapy or not suitable for long-term antiplatelet therapy due to high bleeding risk 6. Patients who are allergic to heparin, poly L-lactic acid (PLLA), sirolimus, antiplatelet drugs, or contrast 7. Currently participating in another trial and not yet at its primary endpoint 8. Patients whose life expectancy is less than 3 years 9. Cardiogenic shock